Category: #MSTreatments

Genentech’s Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

February 7, 2026 – Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of…

Stuart Schlossman

Understanding Brain Health, Exercise and MS Progression – Live event in Atlanta (near airport)

TO RSVP, for this “In-Person” program, PLEASE Click the: Orange RSVP ‘Going’ button, showing down below: Click HERE to View EVENT Flyer *…

Team LIS

Featured image for “Copaxone, Glatopa (glatiramer acetate): Drug Safety Communication – FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis”

Copaxone, Glatopa (glatiramer acetate): Drug Safety Communication – FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis

Treat immediately if symptoms worsen or do not go away shortly after an injection [Posted 01/22/2025] — FDA.GOV AUDIENCE: Patient, Caregiver,…

Stuart Schlossman

Featured image for “A 15-year-old hockey player with MS may never experience a symptom, thanks to Colorado research”

A 15-year-old hockey player with MS may never experience a symptom, thanks to Colorado research

Children’s Hospital Colorado is following 180 people who are siblings or children of people with multiple sclerosis in a breakthrough…

Stuart Schlossman

Featured image for “‘You’re Fine.’ Why Delays in MS Diagnosis Matter.”

‘You’re Fine.’ Why Delays in MS Diagnosis Matter.

by Lisa Doggett Family & lifestyle medicine physician, UT Health MS and Neuroimmunology Center; Sr. Medical Director, Sagility; Author of Up…

Stuart Schlossman

Redefining Relapse in Efficacy Measures for Multiple Sclerosis Treatments

By: Stephen Krieger, MD; Enrique Alvarez, MD, PhD In this poster, Enrique Alvarez, MD, PhD., (from university of Colorado at…

Stuart Schlossman